Cell Reports Medicine (Sep 2024)

Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines

  • Magdalena Schwarzmüller,
  • Cristina Lozano,
  • Merle Schanz,
  • Irene A. Abela,
  • Silvan Grosse-Holz,
  • Selina Epp,
  • Martina Curcio,
  • Jule Greshake,
  • Peter Rusert,
  • Michael Huber,
  • Roger D. Kouyos,
  • Huldrych F. Günthard,
  • Alexandra Trkola

Journal volume & issue
Vol. 5, no. 9
p. 101702

Abstract

Read online

Summary: The development of broadly neutralizing antibody (bnAb)-based therapeutic HIV-1 vaccines and cure concepts depends on monitoring bnAb plasma activity in people with HIV (PWH) on suppressive antiretroviral therapy (ART). To enable this, analytical strategies must be defined to reliably distinguish antibody-based neutralization from drug inhibition. Here, we explore strategies that either utilize drug-resistant viruses or remove drugs from plasma. We develop ART-DEX (ART dissociation and size exclusion), an approach which quantitatively separates drugs from plasma proteins following pH-triggered release allowing accurate definition of antibody-based neutralization. We demonstrate that ART-DEX, alone or combined with ART-resistant viruses, provides a highly effective and scalable means of assessing antibody neutralization during ART. Implementation of ART-DEX in standard neutralization protocols should be considered to enhance the analytical capabilities of studies evaluating bnAb therapeutics and therapeutic vaccines, furthering the development of advanced ART and HIV-1 cure strategies.

Keywords